CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Chinese PLA General Hospital, Beijing, Beijing Municipality, China

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Lymphoplasmacytic Lymphoma · Waldenstrom Macroglobulinemia

Abroad (travel likely)RecruitingPHASE2

Tucson, United States · Tucson, United States

Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma

Advanced Hodgkin Lymphoma · Classic Hodgkin Lymphoma · Lugano Classification Stage III Hodgkin Lymphoma AJCC v8

Abroad (travel likely)RecruitingPHASE2

Irvine, United States · Palo Alto, United States

CAR-T Followed by Bispecific Antibodies

Large B-cell Lymphoma · DLBCL - Diffuse Large B Cell Lymphoma

Abroad (travel likely)RecruitingPHASE2

Omaha, United States · Philadelphia, United States

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Hodgkin Lymphoma · B-Cell Lymphoma · Relapsed B-cell NHL

Abroad (travel likely)RecruitingPHASE2

Houston, United States